Cefditoren pivoxil

Drug Profile

Cefditoren pivoxil

Alternative Names: CDTR-PI; CRTX-062; CRTX-068; ME-1207; Meiact; Spectracef

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Cornerstone Therapeutics; Meiji Seika Pharma; Tedec Meiji
  • Class Antibacterials; Cephems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Respiratory tract infections; Skin and soft tissue infections; Tonsillitis
  • Suspended Pharyngitis
  • No development reported Urinary tract infections

Most Recent Events

  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 31 Mar 2011 Phase-III clinical trials in Bacterial infections (in children) in Japan (PO, Granules)
  • 01 Oct 2010 Meiji Seika Pharma initiates enrolment a phase III trial in Community-acquired pneumonia in Japan (PO) (JapicCTI-101300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top